Articles tagged with Flu Vaccines
Scientists in Vienna have developed a new technique using insect cells to produce vaccines for H1N1 'swine flu', which can meet the demand of a global flu pandemic. This method is faster than traditional egg-based production and offers a safe alternative with reduced biosafety issues.
A study published in JAMA found that a single dose of the H1N1 vaccine may provide sufficient protection for infants and children, reducing transmission of the virus. The researchers assessed the effectiveness and safety of two doses of the vaccine in healthy infants and children, aged six-months to less than 9 years, living in Australia.
Preliminary studies indicate that a single dose of H1N1 influenza vaccine provides sufficient protection for adults, while children under 9 years may require a two-dose vaccination schedule. The vaccine was found to be safe and acceptable in all age groups, with no serious adverse events reported.
A new RAND Corporation study found that US adults are not being vaccinated against the seasonal flu more often than last year. Despite increased public discussion about the importance of influenza vaccines, only 32% of all U.S. adults and 37% of those recommended to receive a flu vaccination had been inoculated by mid-November.
Researchers found that targeting young adults between 20-59 years for vaccinations could help mitigate the impact of ongoing pandemic waves, resulting in a 37% reduction in hospitalizations and 42% reduction in deaths. The study's adaptive strategy was effective in reducing influenza-related deaths by 35% when compared to traditional s...
A new study found that a moderate level of acceptability for an HIV vaccine exists, but high-risk communities may not automatically accept it. The key factors influencing acceptance are efficacy, side effects, and cost. Education is also crucial to ensure the public trusts the vaccine.
Researchers found that employees participating in a large-scale worksite wellness program had significantly reduced absenteeism days due to illness. The study also estimated cost savings of $414.90 per employee per year.
A majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. Despite this challenge, most (91%) who were unable to get the vaccine say they will try again this year.
Infants born to vaccinated mothers had lower hospitalization rates for influenza, highlighting the effectiveness of flu vaccination during pregnancy. The study found that vaccinating pregnant women significantly reduced hospitalizations in infants under six months old.
A clinical trial has shown that healthy pregnant women mount a robust immune response after receiving just one dose of the 2009 H1N1 influenza vaccine. The vaccine has been well-tolerated and elicits protective immune responses in a significant majority of participants.
Researchers emphasize the importance of considering background rates of adverse events in H1N1 vaccination campaigns to prevent public panic. The study highlights that these background rates can provide valuable information on expected number of events occurring in the absence of any vaccination program.
MedImmune to present four abstracts on respiratory syncytial virus (RSV) and influenza prevention at the 47th Annual IDSA Meeting. The studies highlight innovative healthcare solutions for respiratory infections in children. Abstracts focus on prophylaxis, postmarketing evaluation, whole genome transcriptional analysis, and antibiotic use
A comprehensive review of flu seasons past reveals that pregnant women are at significant risk for serious flu-related illnesses and complications, which far surpass the risks associated with injectable vaccines. The study confirms existing CDC recommendations for prioritizing pregnant women in flu vaccination.
A controversial theory suggests that vaccinating children against seasonal flu could prevent the development of heterosubtypic immunity to pandemic strains. However, experts disagree, arguing that vaccination is a definite benefit for preventing seasonal flu infections. The debate highlights the need for more effective influenza vaccines.
Researchers found that high-affinity mutant viruses alternate with low-affinity forms in antigenic drift. Increasing child vaccination could slow this process and extend seasonal influenza vaccine effectiveness.
A new study reveals a relationship between the evolution of the influenza virus and immunization rates needed to prevent outbreaks. The research team found that the degree of variability in population immunity plays a crucial role in determining the risk of an outbreak.
Despite high risk, older African Americans are less likely to get the flu vaccine due to lack of accurate information and lingering distrust from the infamous Tuskegee syphilis studies. This results in lower vaccination rates among this age group, with only 48% vaccinated compared to 65% for non-Hispanic white seniors.
A new study found that nearly half of high-risk American adults who intend to get vaccinated against seasonal flu actually do, but nearly 45% cite a perceived lack of need as the main reason for not being vaccinated. The researchers suggest that educating these individuals about the benefits of vaccination and making it more convenient...
Randomized controlled trials show prophylactic paracetamol administration can reduce fever and antibody responses to vaccines in children, but also highlights the need for careful weighing of benefits and risks. The study concludes that prophylactic use should no longer be routinely recommended.
A simulation model shows that early action and rapid vaccine rollout are extremely effective in reducing the attack rate of the H1N1 influenza virus. The model predicts that vaccination can have a disproportionately large impact on reducing infection rates, especially when implemented quickly.
The National Institutes of Health is launching a clinical trial to find the ideal dose of the 2009 H1N1 influenza vaccine for individuals with severe asthma. The study aims to assess the immune response and safety of two different doses of the vaccine in participants with mild, moderate, or severe asthma.
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting clinical trials to test the safety and efficacy of the 2009 H1N1 influenza vaccine in HIV-infected pregnant women and children, youth. The trials aim to determine whether higher doses of the vaccine can elicit a protective immune response in these populations.
A new study from Trudeau Institute reveals that older animals' immune cells live longer but acquire functional defects. This research may provide new targets to boost immune system function in older individuals, improving vaccine efficacy.
A new study by Stanford University scientists found that starting a vaccination campaign a few weeks earlier could save almost 600 lives and over $150 million. Vaccinating sooner rather than later provides the best strategy to save lives and dollars in flu pandemics.
A survey found that only 40% of adults are confident in getting the H1N1 vaccine for themselves. Concerns about side effects, risk of illness, and vaccine safety top the list among those unsure or opposed to vaccination. The public's interest in the vaccine may increase if an outbreak becomes severe.
A fraction of potential vaccine supply will be ready for distribution by October, but generous pledges from nine countries and two manufacturers will help protect vulnerable populations. The H1N1 virus is expected to infect one-third of the world's population, highlighting the need for effective vaccination strategies.
A majority of Americans are unwilling to take an H1N1 flu vaccine or drug additive authorized for emergency use, citing concerns about safety and effectiveness. The survey found that nearly 30% of respondents remained undecided, while 70% of those who expressed worry would refuse the vaccine outright.
Preliminary analysis of blood samples from trial participants suggests that the 2009 H1N1 influenza vaccine generates an immune response that is expected to be protective against the virus in most children between 10-17 years old. Younger children had a less robust early response to the vaccine.
A systematic review of evidence found that flu can trigger heart attacks and cause cardiovascular death, but the influenza vaccine may reduce this risk. The review suggests that vaccination should be encouraged in people with existing cardiovascular disease, particularly during seasonal flu outbreaks.
The 2009 H1N1 influenza vaccines have demonstrated a strong immune response in most healthy adults when administered in a single dose, with robust protection observed in both younger and older adults. The early data from clinical trials indicate that the vaccines are well-tolerated.
A 70% vaccination rate in the US population, targeting children and high-risk groups, could slow pandemic H1N1 spread. Vaccination is more effective than social distancing measures in controlling the epidemic.
The NIAID is conducting a trial to test the safety and efficacy of a 2009 H1N1 influenza vaccine in pregnant women. The trial aims to provide critical information for public health planning, as pregnant women are at higher risk of developing severe illness from the flu virus.
Rice University bioengineer Michael Deem has developed a technique to predict the efficacy of H1N1 vaccines by estimating antigenic distance between flu strains. This method assigns a numerical value to the similarity between epitope regions, allowing researchers to refine cell-based approaches and shorten vaccine production time.
The American Academy of Neurology and the US Centers for Disease Control and Prevention are monitoring H1N1 vaccine safety for Guillain-Barré syndrome. Neurologists are urged to report any new cases following vaccination, as a precautionary measure due to the association between GBS and previous pandemic vaccines.
Microbiologists at the University of Texas Health Science Center have discovered a cellular molecule called NOD2 that recognizes two common respiratory viruses and directs cells to mount a defense. The finding holds promise for new therapies against human RSV and influenza A, particularly among vulnerable populations.
A new study found that universal influenza vaccination in Ontario, Canada, led to a 64% decline in antibiotic prescriptions and a 39% reduction in influenza-associated mortality. This suggests that increasing flu vaccination rates could help combat antibiotic overuse and related public health concerns.
A new study by Clemson University mathematician Jan Medlock and colleague Alison Galvani recommends prioritizing vaccinations for schoolchildren and adults aged 30-39 to control the spread of seasonal flu and H1N1. The researchers found that these age groups are crucial in preventing transmission, which can lead to severe symptoms amon...
Scientists have designed a painless microneedle patch that can deliver vaccines and medications through the skin, offering a potential solution to painful injections. The patch uses tiny 'microneedles' to improve treatment of diseases such as diabetes and macular degeneration.
Scientists have developed a new vaccine production technology using tobacco plants to combat norovirus, which can spread rapidly through passenger liners and schools. The plant-based vaccine offers cost advantages and could lead to faster and more efficient vaccine development for other diseases.
A dry powder inhalable measles vaccine is being developed for clinical trials in India, which could save millions of lives annually. The vaccine uses a patented process called CAN-BD to create an inhalable powder that can be administered via a simple inhaler.
Patients with systemic lupus erythematosus (SLE) exhibit diminished immune responses to the flu vaccine, including lower antibody and cell-mediated responses. The study found that vaccination did not induce disease activity, but may increase morbidity and mortality due to influenza infection in these patients.
Countries are urged to prioritize post-marketing surveillance to address H1N1 vaccine safety concerns. The US is advised to support dose-sparing strategies to avoid depletion of the already short vaccine supply.
The National Institute of Allergy and Infectious Diseases (NIAID) will conduct a series of clinical trials to test two candidate H1N1 flu vaccines. The trials will evaluate the safety and ability to induce protective immune responses in healthy adults and elderly individuals.
Studies indicate that immunosuppressed populations, including HIV/AIDS patients, cancer patients, transplant recipients, and those on haemodialysis, are at higher risk for flu infection. Vaccination has shown promise in reducing flu cases, but more research is needed to assess vaccine efficacy and timing for optimal protection.
The US military's influenza monitoring system has made notable contributions to global control through collaboration with CDC, FDA, and WHO. The Department of Defense Global Emerging Infections Surveillance and Response System (DoD-GEIS) program provides six objectives relevant to influenza, including laboratory-based surveillance and ...
A study published in the New England Journal of Medicine reveals an age shift in swine flu cases, with younger populations (5-59 years) being disproportionately affected. The findings suggest a need for revised public health strategies to mitigate the impact of future pandemic waves.
A study by the CDC found that only 33.9% of adults with asthma received the flu vaccine in 2007, compared to 54.7% for those without asthma. The study also revealed a significant race/ethnicity gap in vaccination rates among non-Hispanic whites.
Researchers suggest vaccinating children could be an effective way to support pandemic control measures. Vaccination programs for children would offer protection not only to those at greatest risk but also to unvaccinated adults, reducing the need for vaccines in the general population.
Researchers suggest targeting children for flu vaccination to support control measures and reduce pandemic spread. Vaccinating key individuals in households provides sufficient protection to others, potentially reducing the need for widespread vaccination.
Researchers at The Wistar Institute have defined a key target of an evolutionarily conserved protein that regulates the process of aging. Deacetylation of histone H4K16 by Sir2 maintains telomere stability, crucial for yeast cells to replicate and live longer.
IDO enzyme can hinder flu vaccine efficacy by suppressing T-cell response, researchers say. The team plans to block IDO using inhibitors to build better vaccines.
The Government of Canada has funded a national influenza research network to evaluate the safety and effectiveness of pandemic influenza vaccines. The network, led by Dr. Scott Halperin, will provide a pan-Canadian coordinating mechanism for conducting applied public health research on the H1N1 flu virus.
Several companies, including Replikins and Novavax, are working on H1N1 vaccines with varying approaches. The need for a vaccine was prompted by the World Health Organization's Phase 5 pandemic alert.
A new study found that flu vaccines are no more effective in preventing hospitalizations in children with asthma than in those without the condition. The research suggests that vaccination may actually increase the risk of hospitalization among asthmatic children.
World-renowned virologist Professor Albert Osterhaus emphasizes the importance of preparedness in the face of swine-origin flu. He stresses that there is room for improvement in influenza vaccine production and that adequate stockpiles of antibiotics, antivirals, and vaccines are crucial for effective treatment.
A novel vaccine strategy using VLPs could provide a more robust immune response and shorter development time compared to traditional vaccines. Researchers have already made VLP vaccines that show complete protection against H5N1 and 1918 influenza viruses.
A recent study found that infants who receive the pneumococcal conjugate vaccine (PCV) after the DPTaP-Hib vaccine experience less pain than those who receive it first. The authors suggest varying the order of vaccine administration to reduce pain.
Researchers are working on a novel flu vaccine that uses cell culture-based technology to produce immune-boosting signals on the surface of the virus. The goal is to provide better protection against viral pneumonia, especially in elderly populations.
Researchers at Saint Louis University have developed a universal influenza vaccine that evokes high antibody titers, similar to those found in small animals infected with the disease. The vaccine, known as BIPCV, is well-tolerated and safe, even at low doses.
A new study published by the University of Leicester suggests that a six-month time lag may occur before effective vaccines can be manufactured during a pandemic flu outbreak. The study proposes a pre-pandemic vaccination approach to mitigate the worst effects of pandemic flu, which could potentially protect people years in advance.